



 Bristol Myers Squibb™

2024-2025

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS
Institute for Pharmaceutical
Industry Fellowships

Letter From Senior Leadership



Dear Prospective Fellow,

On behalf of Bristol Myers Squibb (BMS) and the Ernest Mario School of Pharmacy, we would like to thank you for your interest in the Post-Doctoral Pharmaceutical Industry Fellowship Program. The pharmaceutical industry provides many exciting and dynamic opportunities, and the same is true at BMS in particular.

BMS truly differentiates itself by combining the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company. We never give up in our search for the next innovation that could mean new hope for patients who are urgently seeking new treatment options today. Constantly pushing the boundaries of scientific excellence, our medicines help millions of people in their fight against serious diseases. Focused on addressing areas of significant unmet medical need, we have exciting development programs in areas such as oncology, hematology, immunology and cardiovascular diseases.

We recognize the importance of social responsibility and the innovative medicines we create. Our belief that “the priceless ingredient of every product is the integrity of its maker,” shines through in how we hold ourselves to the highest standard of integrity. We are not only committed to making a difference in the lives of patients, but also in the global communities where we operate.

BMS places an equal commitment to the development of the individuals who work with us. To meet our mission of helping patients prevail over serious diseases, we are committed to developing a workforce that is diverse, inclusive and representative of the communities in which we operate. We want employees to bring their authentic selves to work and to use their perspectives to contribute in a unique and meaningful way to our mission. We champion these efforts at the highest levels of our organization to ensure our people are engaged and empowered.

Over the past +25 years, we have been creating a best-in-class fellowship program devoted to preparing unique and highly motivated individuals, like yourself, for a rewarding and successful career in our industry.

On behalf of everyone at BMS, we invite you to strongly consider joining our community of people working together to transform the lives of patients through one of the fellowships we offer with Rutgers, Ernest Mario School of Pharmacy. We wish you the best of luck during the recruitment process.

Sincerely,
Chris Boerner, Ph.D.
EVP, Chief Operating Officer



Table of Contents

ABOUT BRISTOL MYERS SQUIBB	4
PROGRAM DESCRIPTION	
Marketed Products & Innovative Pipeline.....	5
BMS Fellowship Campus Locations.....	6
Post-Doctoral Program Governance.....	7-8
RECRUITING OPPORTUNITIES	9
COMMERCIAL	10
Commercial Business Insights & Analytics.....	11
US Market Access.....	12
US Marketing.....	13
CLINICAL DEVELOPMENT	14
Global Drug Development.....	15
MEDICAL	16
Global Medical Education & US Oncology Medical Strategy.....	17
US Cardiovascular Medical Strategy & Field Medical Sciences.....	18
US & Worldwide Medical Strategy: Immunology.....	19
Worldwide & US Hematology/Oncology: Medical Communications/Field Medical.....	20
Worldwide & US Medical Strategy: Oncology.....	21
Medical Communications – Scientific Content & HEOR Publications.....	22
US & Worldwide Hematology Medical Affairs.....	23
US Immunology Field Medical & Medical Evidence Generation (MEG).....	24
REGULATORY	25
Global Regulatory Strategy.....	26
US Commercial Regulatory Affairs: Advertising & Promotion.....	27
CORPORATE AFFAIRS	28
Policy & Patient Advocacy.....	29
BMS RESIDENCY	30
Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency.....	31
NON-RECRUITING FELLOWSHIPS	32
LEADERSHIP SPOTLIGHT	33
RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB	34-35
BRISTOL MYERS SQUIBB COMPONENT	36
RUTGERS COMPONENT	37-38

About Bristol Myers Squibb

Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Commitment

To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our diverse and inclusive culture supports better outcomes for all patients and we seek diversity in all aspects of our business.

Our Biopharma Success

At Bristol Myers Squibb, we uniquely combine the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers' needs, giving maximum priority to accelerating pipeline development, delivering sales growth, and continuing to manage costs. In recent years, we have outperformed most mega pharma companies, diversified companies, and pure biotech companies, having delivered 14 new medicines to patients since 2002. We are a BioPharma leader with a commitment to patients with serious disease, focused on finding innovative medicines to address unmet medical needs. Having transformed Bristol Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities with a commitment to making a meaningful difference in the lives of our patients. Continuous innovation is critical to our BioPharma strategy and is enhanced by our diverse workforce and inclusive culture. Over the years, Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions, including being named one of the 50 Smartest Companies in 2015, as a leader in Immuno-oncology. Furthermore, we have the honor of continuing a legacy as one of the 100 Best Corporate Citizens, maintaining a perfect score on the Corporate Equality Index, and having been recently named one of the World's Most Admired Companies.



Marketed Products & Innovative Pipeline

Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Immunology, Cardiovascular, and Fibrosis.

150+

PROJECTS IN CLINICAL DEVELOPMENT

841M

PATIENTS REACHED THROUGH ACCESS & EDUCATION PROGRAMS

9.5B

IN RESEARCH & DEVELOPEMENT SPEND

50+ INVESTIGATIONAL THERAPIES

[SEE OUR FULL PIPELINE HERE](#)

Cutting edge technologies & discovery platforms

- Cell & gene therapy
- Protein homeostasis
- Biologics
- Small molecules
- Chemistry

Therapeutic areas with unmet needs

- Oncology
- Hematology
- Cardiovascular
- Immunology
- Fibrotic diseases
- Neuroscience

IMMUNOLOGY



CARDIOVASCULAR



HEMATOLOGY



ONCOLOGY



CELL THERAPY



BMS Fellowship, Primary Campus Location

Princeton Pike (PPK)

Lawrenceville, NJ





Post-Doctoral Program Governance

Executive Steering Committee



Melissa Harris, PharmD
Senior Vice President,
Regional Clinical
Operations

Steering Committee Leads



Priya Darouian, PharmD
Director, Medical
Innovation



Thomas Lehman, PharmD
Senior Director,
WW Medical,
Rheumatology

Steering Committee Members



Cathy Merrill, PharmD
Director, Early Transition
Assets/Rela WW Scientific
Publications



Matt Lupo, MCIS
Executive Director, US
Commercial Regulatory
Affairs



Ijeoma Oyetunde, PharmD
Director, WW Medical,
Oncology



July Kim, PharmD
Senior Director,
Medical Promotional
Review Lead,
Hematology



Victoria Berger, PharmD
Senior Clinical Scientist



Peter Fendt, PharmD
Associate Director,
Commercialization
Analytics, Hematology/
CAR-T



Kim Tran, PharmD
Executive Director,
US Field Medical
Hematology



Second-Year Co-Chief Fellows

**Moksha Patel,
PharmD**

Second-Year Fellow
US Cardiovascular Medical
Strategy and Field Medical
Sciences

**Asia Ridley,
PharmD**

Second-Year Fellow
Global & US Medical Strategy:
Oncology

**Hannah Roeder,
PharmD**

Second-Year Fellow
BIA: US Cell Therapy
Market Research



2024-2025

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM





COMMERCIAL

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM



Commercial Business Insights & Analytics



Hannah Roeder, PharmD

Second-Year Fellow
University of North Carolina
Eshelman School of Pharmacy

At BMS, the Commercial Business Insights & Analytics (BI&A) division fuels bold decisions to create a competitive advantage and accelerate growth. This joint two-year fellowship is a unique opportunity for a Fellow to identify insights and work with others to translate these findings into actionable recommendations for senior management. The Fellow will lead critical projects on cross-functional teams with individuals from Marketing, Market Research, Forecasting, Access, Medical Affairs, Business Development, and R&D Clinical Development.

The Fellow will spend the first year in Commercialization Competitive Intelligence and the second year in Market Research. While on both teams, the Fellow will synthesize data from both primary and secondary sources to develop actionable recommendations for business stakeholders. These rotational opportunities will allow the Fellow to help provide strategic partnerships and understand procedures within the BI&A organization.

COMPETITIVE INTELLIGENCE

- Monitor and assess the competitive environment, market trends, and emerging scientific data to inform clinical, medical, and commercial strategies
- Provide real-time context and implications of key market events to stakeholders and broader cross-functional teams to catalyze discussion and potential strategic responses
- Plan and execute coverage of congresses to provide insights on key business questions that support brand or therapeutic area goals
- Communicate regularly with key stakeholders to identify gaps in knowledge and develop solutions to support business-critical activities

MARKET RESEARCH

- Work closely with cross-functional teams in Marketing, Medical, Sales, Forecasting, and Access to understand business needs and design various market research projects that address key business questions
- Manage and analyze primary research projects with vendor partners to effectively communicate insightful reports and presentations to guide brand strategies
- Maintain knowledge across the market and competitive trends to adapt to the dynamic customer environment
- Create, synthesize, and develop new market research techniques, solutions, and methods

The Fellow will develop valuable skills and experiences in identifying and prioritizing business opportunities and gaps. The Fellow will also develop transferable skills, including project management, vendor management, and enhanced presentation skills

PRECEPTORS:

- **Wilfredo Ortiz, PhD**
Director, Competitive Intelligence, Cardiovascular & Neurology
- **Peter Fendt, PharmD**
Associate Director, Commercialization Analytics, Hematology/CAR-T



Victoria Woo, PharmD

First-Year Fellow
Rutgers University Ernest
Mario School of Pharmacy

US Market Access



Josh Dadural, PharmD
 Second-Year Fellow
 University of Florida
 College of Pharmacy

This two-year fellowship offers the opportunity to join a rapidly-evolving access organization that leads in the industry to ensure patient and provider access to therapy. Within the fellowship program, the Fellow will have the opportunity to gain experience working in multiple components of the organization, with an emphasis in Hematology and Oncology. Through three rotational opportunities, the Fellow will build core foundational marketing skills, develop a comprehensive understanding of drug pricing, payer-provider reimbursement, and patient affordability. Additionally, the Fellow will gain exposure to many unique experiences and gain valuable insight into tactics and cross-matrix initiatives used to ensure patient access to quality care.

The fellowship is structured in flexible rotations within the core US market access teams which includes Patient Access Support Services, Pricing & Contracting, and Access Marketing. During this program, the Fellow will:

PATIENT ACCESS SUPPORT SERVICES

- Evaluate the evolving healthcare landscape to assess the implications for provider reimbursement and patient affordability
- Create materials, including both traditional and digital content, to communicate the proper billing and coding for infusible products to support launch and label updates

PRICING & CONTRACTING

- Understand challenges and business drivers across multiple channels including Payers, Integrated Delivery Networks, Group Purchasing Organizations, and Pathway organizations
- Gain experience in economic modeling to shape pricing strategy for new and existing products based upon shifting marketplace pressures and dynamics

ACCESS STRATEGY

- Contribute to the brand payer strategy by evaluating payer management trends, emerging access influencers, and the evolving competitive landscape
- Interact with medical strategy, health economics and outcomes research, and market research to develop promotional materials communicating the value of our products to managed care organizations

ADDITIONAL EXPERIENCES

- Engage in field rides with external stakeholders alongside Access Reimbursement Managers, Health Systems Liaisons, and Account Executives
- Participate in potential opportunities with US market access matrix teams such as US Federal Policy, US Oncology Brand Marketing, and Global Market Access

PRECEPTORS:

- **Greg Long, MBA**
 Vice President, Access Strategy, Hematology, CAR-T, & Oncology
- **Fred Zeleznik, MBA**
 Vice President, Global Pricing Execution
- **Snehal Patel, PharmD**
 Executive Director, Patient Access Support Services



Amie Lette, PharmD, MS
 First-Year Fellow
 University of Maryland
 School of Pharmacy



US Marketing

This two-year fellowship offers you the opportunity to join an innovative and patient-centered organization that continues to remain at the forefront of unprecedented advancements. You will have a unique opportunity to leverage your clinical knowledge in order to contribute to and lead critical commercial efforts that drive brand performance. This fellowship provides the development of core pharmaceutical marketing and business skills, the opportunity to collaborate with senior leaders as well as the ability to gain exposure to team members across various functional areas that span the broader Bristol Myers Squibb organization.

Specifically, in this role you will:

- Shape the development of impactful commercial strategies
- Support and lead various executions of marketing plans focused on healthcare professionals, including interactions with the sales force
- Utilize market research learnings and competitive insights to identify potential opportunities and challenges in the market
- Manage creative agency partners and champion materials through the promotional review process in collaboration with medical, regulatory, and legal colleagues

PRECEPTOR:

- **Evelyn Abramson, PharmD**
(Advisor) Senior Manager, US Oncology Marketing

*Preceptor to be determined





CLINICAL DEVELOPMENT

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM





Global Drug Development



Camryn Joseph, PharmD
 Second-Year Fellow
 Florida A&M University College of
 Pharmacy & Pharmaceutical Sciences



Nishanth Viswanath, PharmD
 Second-Year Fellow
 St. John's University
 College of Pharmacy and Health Sciences



Victoria MacLelland, PharmD
 First-Year Fellow
 University of Saint Joseph, School of
 Pharmacy and Physician Assistant Studies



Yasmin Pirestani, PharmD
 First-Year Fellow
 Thomas Jefferson University

The Global Drug Development (GDD) organization is responsible for developing new medicines for the treatment of various diseases worldwide. Fellows within GDD function as Associate Clinical Scientists (CS) would focus on the science and strategy of drug development. The Fellows will learn various aspects of global clinical studies (Phases III) including study initiation, maintenance, and closure activities.

GLOBAL DRUG DEVELOPMENT FELLOWSHIP OBJECTIVES:

- Understand the key foundations of clinical trial development and how they relate to the overall drug development process (i.e. study design, selecting study endpoints, randomization/stratification, control, blinding, selection of population, and study assessments).
- Become a proficient CS and effective cross-functional study team contributor throughout the clinical trial process by learning to develop study protocols and protocol amendments, informed consent forms, patient narratives, clinical study reports (CSR), Investigator Brochures (IB), Investigational New Drug (IND) safety updates, Development Safety Update Report (DSUR), and other regulatory submission documents.
- Work closely with the CS's, CTP's (Clinical Trial Physician) and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences.
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports and data listings.
- Partner with Clinical Operations, Data Management, Statistics, Drug Safety, Regulatory, Clinical Pharmacology, Medical Writing and Marketing team to support the scientific aspects of clinical development.

The Global Drug Development fellowship is a 2-year program primarily focused on developing new therapies in solid tumor oncology, cellular therapy, cardiovascular & neuroscience and immunology, where there is a large unmet need. Bristol Myers Squibb is at the forefront of drug research with an extensive and quickly developing pipeline. This fellowship opportunity will allow the Fellows to work on novel and innovate therapies to transform treatment landscapes.

Solid Tumor Oncology GDD: Recruiting 1 Fellow
 Cellular Therapy GDD: Recruiting 1 Fellow
 Cardiovascular & Neuroscience GDD: Not recruiting
 Immunology GDD: Not recruiting

PRECEPTORS:

- **Jeffrey Anderson, MD, PhD**
 Executive Director, Opdivo Clinical Science Program Lead, Oncology
- **Brenda Yuan, PharmD**
 Clinical Scientist, Cellular Therapy
- **John Pribble, PharmD**
 Senior Director, Breyanzi Clinical Science Program Lead, Cellular Therapy



MEDICAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Global Medical Education & US Oncology Medical Strategy



Ruchi Shah, PharmD

Second-Year Fellow
Rutgers University Ernest Mario
School of Pharmacy



Sam Pike, PharmD

First-Year Fellow
University of Michigan College
of Pharmacy

The Global Medical Education and US Medical Oncology Pan Tumor Strategy position is a 2-year fellowship that ensures an integrated approach in aligning efforts throughout the medical organization. The Fellow will be able to aid the medical teams in developing medical strategies for our marketed products as well as the assets in our pipeline, execute effective launches, support healthcare provider (HCP) education and ensure the safe and appropriate use of our medicines by HCPs and patients. This fellowship will provide rotational experiences in two key teams within the medical organization: Independent Medical Education (IME) for 8 months and US Medical Oncology Pan Tumor Strategy for 15 months. During this program, the Fellow will:

INDEPENDENT MEDICAL EDUCATION

- Understand the roles and responsibilities of an IME department in the pharmaceutical industry
- Execute processes and procedures related to medical education grants
- Understand IME medical strategy and functional plan
- Develop proficiency in grant review, know what a robust grant consists of, and understand the learning science of Adult Learning Principles
- Execute a request for education (RFE) process from start to finish
- Analyze outcomes data from BMS-supported medical education activities. Communicate behavioral changes, competence/knowledge gains, learner questions and remaining education gaps to the medical matrix teams
- Attend/evaluate continuing medical education programs supported by BMS assessing for compliance, fair-balance, and quality of supported medical education programs
- Interface with medical education communication companies to understand provider capabilities and assess outcomes of activities

PAN TUMOR MEDICAL STRATEGY

- Engage in medical strategy tactics, including thought leader interactions, advisory board discussions, gathering field therapeutic area insights, and aligning with oncology medical partners on safety/patient management, dosing, and other pan tumor topics
- Lead the strategic communication, collaboration, and awareness of pan tumor efforts while partnering on execution with functional teams including US and Worldwide Medical, Clinical Development, Commercial, Publications, Medical Information, and Field Medical
- Participate in the execution of pan tumor related deliverables including proactive patient management materials, medical proactive/reactive decks, and training materials for cross-matrix colleagues

PRECEPTORS:

- **Maria Deutsch, MS, PharmD, RPh**
Director, Global Medical Excellence & Policy, Medical Education, Oncology
- **Max Prokopovich, PharmD**
Associate Director, US Medical Oncology, Pan Tumor
- **Nabomita Thomas, PharmD, RPh**
Sr Director, US Medical Oncology, Pan Tumor



US Cardiovascular Medical Strategy & Field Medical Sciences



Moksha Patel, PharmD
 Second-Year Fellow
 Rutgers University Ernest Mario School of Pharmacy



Tia Belvin, PharmD
 First-Year Fellow
 University of North Carolina Eshelman School of Pharmacy

This two-year fellowship provides a unique opportunity to develop experiences in strategic in-house medical affairs and field medical settings. The Fellow will acquire cardiovascular disease state knowledge and master the BMS cardiovascular product portfolio, including a launch product in a rare disease state. In addition, the Fellow will work on high priority projects and initiatives aligned with the Medical Plan to support impactful HCP interactions. The Fellow will develop leadership and communication skills through collaboration across the US Medical matrix teams and other key partners. Key activities and learnings will include:

MEDICAL STRATEGY

- Participate in the US Medical matrix team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Support the execution of the Medical Strategy tactical plan by working across matrix teams (Marketing, Field Medical, Independent Medical Education, Advocacy, Clinical Development, Legal and Regulatory) as well as with alliance partners
- Collaborate with cross-functional medical team members to deliver on key medical initiatives, including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Support development of medical training materials for sales representatives and deliver medical presentations at sales training sessions
- Contribute towards congress strategy and lead the execution of National and International Congress planning activities as part of the CV Medical Plan

FIELD MEDICAL SCIENCES

- Complete MSL trainings and certification processes for the CV profile
- Engage thought leaders in scientific discussions during field-based activities with CV MSLs
- Assess/identify gaps in MSL resources and collaborate with medical strategy on the development of MSL scientific resources and trainings
- Collaborate with the Field Medical Leadership Team to support development and implementation of field medical priorities
- Contribute to scientific congress Field Medical initiatives

PRECEPTORS:

- **Ajay Shukla, PharmD**
 Director, Medical Strategy, Established Brands
- **April Adams, PharmD**
 Senior Director, US Field Medical, Cardiovascular
- **Patricia Schuler, PharmD**
 Director, Medical Strategy Camzyos, US Cardiovascular Medical

US & Worldwide Medical Strategy: Immunology



Rachel Goldberg, PharmD
 Second-Year Fellow
 University of Illinois Chicago
 College of Pharmacy

This two-year fellowship provides a unique opportunity to work in two of the most exciting and competitive areas of immunology research and pharmaceutical development today: Dermatology and Rheumatology. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through both participatory and leadership experiences from the perspective of both the US and Worldwide Medical Strategy Teams. During the fellowship, the Fellow is expected to experience several important market events including post-launch support in dermatology and several phase 2/phase 3 study read outs. Graduates of this fellowship have gone on to lead successful careers in various aspects of Medical Affairs including Medical Strategy, Scientific Communications, Clinical Development, Medical Science Liaison, Medical Information, and Independent Medical Education.

US MEDICAL STRATEGY – DERMATOLOGY

- Participate in strategic planning with the US Medical Matrix Team based on unmet medical needs from the perspectives of patients, providers, and payers
- Lead medical projects in partnership with the broader medical matrix team members (Field Medical, Medical Information, Independent Medical Education, Sales, Marketing, Outcomes Research, Promotional Integrity, Legal, and Global Pharmacovigilance & Epidemiology)
- Lead and participate in key aspects of medical affairs including data generation, content development, training, insight reporting, advisory boards, and congress planning
- Conduct medical review of promotional and non-promotional materials in collaboration with Legal, Regulatory, and Marketing teams



Somto Egbuonu, PharmD
 First-Year Fellow
 Texas Tech University Health
 Sciences Center

WORLDWIDE MEDICAL STRATEGY – DERMATOLOGY & RHEUMATOLOGY

- Lead development and execution of the Global Medical Plan in partnership with key international market teams (eg, US, EU, Asia-Pacific), Clinical Development, & Commercial
- Prepare for a commercial launch and several Phase 2/3 data releases for deucravacitinib (a selective TYK2 inhibitor) in Rheumatology
- Engage International Key Opinion Leaders via advisory boards, steering committees, MSLs, and international conferences to inform and elevate BMS strategy
- Identify educational needs among Rheumatologists and Dermatologists and execute plans to fulfill them; eg, disease education, pathway materials, conference symposia, review articles
- Develop integrated data generation plans and review/approve investigator sponsored research proposals to inform appropriate use of BMS medicines and fulfill unmet medical needs

PRECEPTORS:

- **Keith Wittstock, PharmD, MBA**
 Associate Director, Deucravacitinib US Medical Strategy
- **Samantha Pomponi, PharmD**
 Associate Director, Deucravacitinib and Orenicia WW Medical Strategy

Worldwide & US Hematology/Oncology: Medical Communications/Field Medical



Jordan Simpson, PharmD
Second-Year Fellow
Texas Southern University
College of Pharmacy and Health
Sciences



Joanne Lu, PharmD
First-Year Fellow
University of Maryland, School
of Pharmacy

This two-year fellowship provides an opportunity to develop an understanding of the functional areas of Medical Communications and Field Medical. Fellows will be afforded the opportunity to build a strong foundation from their first-year experiences in medical communications, as well as through early exposure to field interactions, that can be leveraged as they transition into a field-based role during the second year of the fellowship. Throughout the course of this fellowship, individuals will not only acquire disease state knowledge, but also master clinical data regarding Bristol Myers Squibb and competitor products. Fellows will collaborate within a cross-functional matrix (eg, Legal/Regulatory, Medical, Clinical Development, and R&D) through leading Fellow-driven projects with demonstrable business impact.

MEDICAL COMMUNICATIONS

- Function as a Medical Communications lead to enable the healthcare community to advance the science, accelerate access, shape medical practice, and drive appropriate adoption of Bristol Myers Squibb medicines
- Manage across a global matrix organization (eg, Legal, Medical, Clinical Development, Translational) to drive quality planning and timely delivery of strategically aligned medical communications, including publications, congress presentations, and scientific content (e.g., standard response documents, Q&As, and reactive slide decks)
- Partner closely with the medical information contact center in responding to unsolicited requests from HCPs, payers, and patients
- Understand the communication needs across the therapeutic area and disease area that incorporate and align with enterprise-level strategies for the development and execution of functionally integrated medical communication plans, with application and pull-through to Scientific Communication Platforms and Scientific Narratives

US FIELD MEDICAL ONCOLOGY

- Field interaction opportunities with Medical Science Liaisons to obtain experience in the engagement of oncology thought leaders and other key members of the oncology healthcare team.
- Play a critical role in the collection and analysis of insights, Medical Account Planning, and tumor specific training to gain an understanding of the market and therapeutic landscape, including development of quarterly TACTIC newsletter
- Work directly on headquarters-based field medical projects, and attend key Bristol Myers Squibb meetings (i.e., National Oncology Meetings, Medical Congresses, Continuing Medical Education, Medical Matrix collaboration, and Medical Science Liaison training)
- Participate in weekly Field Medical meetings (regional calls, journal clubs, and national meetings).
- Demonstrate mentorship as co-preceptor for APPE student rotations
- Analyze key field metrics with FM Leadership Team and understand business impact

PRECEPTORS:

- **Avani Patel, PharmD**
Associate Director, Oncology Field Medical Strategy
- **Dana Francis, PhD**
Associate Director, Medical Communications, Hematology Early Asset Portfolio

Worldwide & US Medical Strategy: Oncology



Asia Ridley, PharmD

Second-Year Fellow
Florida A&M University
College of Pharmacy &
Pharmaceutical Sciences

Medical Strategy is where scientific and clinical knowledge meet strategic application. This two-year fellowship provides a unique opportunity to support the development and execution of Worldwide and US Oncology Medical Strategy and other medical activities. During the first year in Worldwide Medical Oncology, the Fellow will focus on developing the global strategy for new indications in a wide array of tumor types through collaborative efforts with BMS regional offices around the world. During the second year in US Medical Oncology, the Fellow will focus on developing and executing the US strategy for the successful launch and continued support of a wide range of indications through Medical Engagements, Conferences, and Launches. Throughout these 2 years, the Fellow will gain exposure to various stakeholders and develop leadership skills by supporting and leading medical initiatives in collaboration with the Worldwide and US cross functional matrix teams (e.g., Clinical Development, Clinical Operations, Regulatory, Medical Publications and Scientific Content, Field Medical, Commercial, HEOR, Competitive Intelligence, Access and more).

WORLDWIDE MEDICAL STRATEGY

- Gain experience in the development of a strategically-aligned Global Medical Plan based upon unmet medical need by collaborating with a cross functional, multi-regional (i.e., US, EU, Asia-Pacific) Worldwide Medical matrix team
- Engage with external Thought Leaders in an effort to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Lead the execution of medical deliverables that are closely aligned with the strategic Global Medical Plan, including National and International Congress planning for activities such as advisory boards, symposia, and TLEs
- Collaborate with BMS country-specific medical colleagues to collect field insights that will support strategic planning and tactical execution
- Actively participate in the review and approval process of Investigator Sponsored Research proposals that are aligned with the data generation plan detailed in the Global Medical Plan

US MEDICAL STRATEGY

- Participate in key medical activities such as medical advisory boards, Field Medical resources and trainings, Congress planning (e.g., ASCO, ASCO GI), reactive content, and the communication strategy, including publications
- Collaborate with US Medical matrix teams (e.g., Field Medical, Data Generation, Patient Advocacy, Medical Education, and Congress Management) to support planning and delivery of medical objectives based on unmet medical needs
- Collaborate and communicate with US Commercialization & Access organizations to integrate medical perspectives into the commercialization process and ensure appropriate alignment between commercial and medical plans
- Engage with external thought leaders and scientific experts to assess unmet medical needs to develop appropriate medical strategies

PRECEPTORS:

- **Irfan Tejani, PharmD, MSc**
Senior Director, WW Medical Oncology, Gastrointestinal Tumors
- **Boas Park, PharmD, MBA**
Director, US Medical Oncology, Gastrointestinal Tumors Portfolio



Caitlin Henley, PharmD

First-Year Fellow
Thomas Jefferson University



Medical Communications – Scientific Content & HEOR Publications



Lilianna Ly, PharmD

Second-Year Fellow
University of Pittsburgh
School of Pharmacy

This two-year fellowship provides an opportunity to work across the Medical Communications group within the Scientific Communications and Engagement organization, where the Fellow will learn how to communicate key clinical and economic data across various channels to inform healthcare decision-making. Within this role, the Fellow will gain an appreciation for how health economics and outcomes research (HEOR) plays a crucial role in assessing disease burden, identifying unmet needs, and demonstrating the clinical and economic value of pharmaceuticals. While doing so, the Fellow will become adept in the planning and execution of scientific communication deliverables, including dossiers, reactive slide decks, congress presentations, and journal publications. The nature of this position encourages the cultivation of critical thinking and leadership skills through cross-functional collaboration with various stakeholders (e.g., Medical Information, HEOR, Medical Strategy, Field Medical, Field HEOR, Access Marketing, and Legal). Key activities and learnings will include:

WORLDWIDE AND US SCIENTIFIC CONTENT

- Understand the unique information needs of healthcare professionals, US payers, and access influencers that can inform reimbursement policies, formulary decisions, and guideline recommendations pertaining to BMS medicines
- Collaborate with HEOR, Medical Strategy, medical field teams, and other stakeholders to ensure development of fair-balanced scientific content with the highest degree of medical integrity, accuracy, and clinical and payer relevance
- Lead content creation of medical communication deliverables involving clinical studies, economic analyses, and real-world evidence pertaining to BMS medicines. Deliverables include AMCP dossiers, Medicaid submissions, submissions to guideline bodies, reactive slide decks, standard response documents, Q&A documents for medical field teams, and responses to medical information inquiries



Raazi Siddiqui, PharmD

First-Year Fellow
Saint Joseph's University,
Philadelphia College of Pharmacy

HEOR PUBLICATIONS

- Gain experience, through collaboration with WW and US HEOR, WW and US Medical Strategy, and other stakeholders, in developing strategic HEOR publication plans for BMS products
- In collaboration with HEOR, external authors, and appropriate internal stakeholders, develop publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts focused on disease burden, unmet medical needs, and the clinical and economic value of BMS products
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

PRECEPTORS:

- **Sandra Ibrahim, PharmD**
Director, Medical Communications
- **David S. Berger, PhD**
Director, Medical Communications

US & Worldwide Hematology Medical Affairs



Jaswitha Basu, PharmD
 Second-Year Fellow
 Temple University School of Pharmacy

The two-year Medical Affairs fellowship is designed to provide broad exposure and opportunities to understand the various roles within the Hematology Medical Affairs organization. Throughout the fellowship, the Fellow will further develop their knowledge base within the hematology space by acquiring disease state knowledge and mastering clinical data involving the Bristol Myers Squibb product portfolio and competitor data. The Fellow will learn various aspects of clinical research (company sponsored trials, investigator-initiated trials, cooperative group trials, and registries) while working collaboratively with medical disease teams and cross-functional partners.

US MEDICAL

- Gain a broad knowledge and understanding of assigned disease areas including, but not limited to: disease biology, currently available therapeutic options, agents in development, and unmet medical needs for specific patient segments
- Gain product-related expertise in each assigned disease area and engage in scientific and strategic discussions with key internal and external stakeholders
- Support the medical disease teams with content preparation and planning for medical congresses (e.g. ASCO, ASH) and other key external meetings, including advisory boards, scientific steering committee meetings, and thought leader engagements
- Collaborate with cross functional team members, including Medical Science Liaisons (MSLs), Scientific Communications, Scientific Education, Medical Information, and Learning & Development teams, to create and execute on medical tactical plans

WORLDWIDE MEDICAL

- Engage with international Key Opinion Leaders via congresses, advisory boards, symposiums
- Identify key data gaps in HCP education and lead execution of plans to educate and inform of BMS strategy
- Contribute to the evaluation of investigator-initiated trial concepts and how each concept strategically relates to open research questions that have been prioritized within the department and disease team

PRECEPTORS:

- **Patrick Liu, PharmD**
Associate Director, US Medical Affairs Myeloid
- **Marie Labib, PharmD**
Senior Manager WW Medical Myeloid

US Immunology Field Medical & Medical Evidence Generation (MEG)



Karandeep Singh, PharmD

First-Year Fellow
St. John's University, College
of Pharmacy and Health Sciences



Chris Higgins, PharmD

First-Year Fellow
Thomas Jefferson University

The Immunology Field Medical & Medical Evidence Generation (MEG) position is a two-year fellowship that will provide a unique opportunity to gain expertise in multiple dimensions of the medical affairs function in the immunology space. During their first year, the fellow will join the US Immunology Field Medical team and participate in key projects, critical to the success of new product/indication launches and currently approved products. The fellow will gain an appreciation for core Field Medical competencies spanning field training, operations, and thought leader(TL)/investigator engagement. In their second year, the fellow will join the MEG team and contribute to the development and implementation of the Integrated Evidence Plan (IEP) and interaction with the different modalities of evidence generation (investigator-sponsored studies, interventional and noninterventional company-sponsored trials, collaborative research, data mining and exploratory analysis among others). During the fellowship, the candidate is expected to participate in multiple important events including phase II and III study read-outs, design, implementation of Phase IIIb/IV studies, and preparation for global launch(es).

US IMMUNOLOGY FIELD MEDICAL

- Serve as an integral part of the Immunology Field Medical Strategy and Training team and key contributor for field medical planning, stakeholder communications, and launch/life-cycle management projects
- Gain product and therapeutic expertise in Immunology as foundational knowledge to apply to various projects and activities
- Collaborate with home office and field matrix teams to assist in the development of training initiatives and medical resources
- Contribute on innovative tactics and/or platforms to elevate MSL development and productivity in the field
- Participate in MSL trainings and assessments. Fellow will have the opportunity to accompany MSLs on field rides and virtual interactions to gain an understanding of diverse experiences with TLs and study investigators

MEDICAL EVIDENCE GENERATION (MEG)

- Support the development, tracking and maintenance of the Integrated Evidence Plans (IEPs) that reflects asset strategy, market priorities and medical evidence generation support in partnership with the I&F Global Medical Disease Team and cross-functional teams including (but not limited to) Global Drug Development (GDD), Translational Development, Health Economics and Outcomes Research (HEOR), and others
- Develop Areas of Interest (AOI) based on key open data questions (ODQ) identified in the IEP with market input in collaboration with the I&F Global Medical Disease Team
- Manage the scientific aspects of the ongoing I&F Investigator-sponsored Research (ISR) book of work and serve as the subject matter expert and interface with all key stakeholders across the matrix
- Conduct regular book of work reviews in partnership with GDO with key medical and development stakeholders, under their remit. Identify studies at risk for failing to meet timelines and negotiated mitigation plans with key internal stakeholders and investigators
- Assist in the reviews of concepts through RFP (Request For Proposals) process, as appropriate, including providing context for ongoing book of work, area of interest development, and upcoming data read-outs

PRECEPTORS:

- **Carlín Walsh, PharmD, BCPS**
Director, US Field Medical Immunology Portfolio Strategy
- **Manisha Patel, RPh, PMP**
Director, Project Management Team – Medical Evidence Generation



REGULATORY

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM



Global Regulatory Strategy



Jessica Zhu, PharmD

Second-Year Fellow
Rutgers University Ernest Mario
School of Pharmacy



Ashley Volpe, PharmD

First-Year Fellow
Fairleigh Dickinson University
School of Pharmacy and
Health Sciences

This two-year fellowship provides the opportunity to establish a broad understanding of Global Regulatory Strategy and its role in the drug development process. The Fellow will obtain direct experience and exposure to products at various stages of development and will learn important considerations for working with key regulatory agencies such as FDA and EMA. Optional rotation(s) in Precision Medicine, Commercial Regulatory Affairs, or Global Labeling, will allow additional experience based on Fellow interest and opportunities. During this program, the Fellow will:

- Participate in the development of global regulatory strategies supporting development, approval, and maintenance of drugs and biologics
- Contribute to identification and assessment of regulatory risks and their mitigation
- Participate in planning and for preparing Health Authority (HA) interactions and assessing impact of HA feedback on an asset's development plan
- Draft submission documents, including for INDs, NDA/BLAs, and expedited regulatory designation requests
- Manage responses to Health Authority queries
- Work with matrix team members (R&D and Non-R&D) to identify solutions that meet regulatory requirements as well as commercial objectives
- Work with Global Regulatory Policy team on reviewing special topics

PRECEPTORS:

- **Amandeep Riar, PharmD**
Associate Director, Global Regulatory Strategy and Policy, Hematology
- **Robert Kalesnik-Orszulak, PharmD**
Senior Director, Global Regulatory Strategy and Policy, Oncology
- **Vrunda Patel, PharmD**
Director, Global Regulatory Strategy and Policy, Immunology



US Commercial Regulatory Affairs: Advertising & Promotion



Tatiana Hines, PharmD

First-Year Fellow

University of North Carolina
Eshelman School of Pharmacy

The US Commercial Regulatory Affairs group at Bristol Myers Squibb provides strategic regulatory guidance within the company on the Food and Drug Administration (FDA) advertising and promotion regulations to support good business practices. The regulatory advice is provided to the marketing organization to ensure the highest level of ethics and integrity in the promotion of Bristol Myers Squibb products. The group collaborates with a variety of functions including Marketing, Medical Affairs, Legal, Global Labeling, Managed Markets, Global Regulatory, Safety, and Biometrics. The Fellow will be assigned to a primary therapeutic area. Key activities and learnings will include:

- Gaining an understanding of and ensuring consistency between key federal regulations and Bristol Myers Squibb policies
- Analyzing the impact of FDA Office of Prescription Drug Promotion (OPDP) enforcement actions and assessing the regulatory implication to commercial activities
- Assisting in the regulatory review of proposed promotional materials and programs created by Marketing, Sales, or Corporate Affairs and submissions to OPDP
- Collaborating with matrix team members to advise on the development of marketing campaigns that meet regulatory requirements as well as commercial objectives

PRECEPTORS:

- **Akshay Patel, PharmD**
Associate Director, US Commercial Regulatory Affairs
- **Alexander Cheung, PharmD**
Senior Manager, US Commercial Regulatory Affairs
- **Cole Cecchini McDoniell, PharmD, M.S.**
Senior Manager, U.S. Commercial Regulatory Affairs





CORPORATE AFFAIRS

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM



Policy & Patient Advocacy



Chinenye Agim, PharmD

Second-Year Fellow
University of South Carolina
College of Pharmacy

This industry leading fellowship provides opportunities to work with seasoned professionals within both US Policy & Government Affairs and Global Patient Advocacy. The Fellow will gain experience working across a matrix team (commercial, clinical development, medical, HEOR, market access, policy, communications and legal) to gather expert patient advocate insights, engage with relevant non-profit organizations, develop advocacy plans that optimize access to high quality medicines for patients and incorporate patient input into the drug development lifecycle continuum. During this time of continued reform and evolution of the U.S. healthcare system, the Fellow will develop a deep understanding of how healthcare policies are developed and implemented within the US, and how they impact patients, providers, payers, the company and the biopharmaceutical industry. The Fellow will interact and collaborate with stakeholders across Bristol Myers Squibb and gain experience working with patient advocacy organizations, professional organizations, trade associations, policy stakeholders and other organizations that contribute to the policymaking process and the overall changing healthcare landscape.

U.S. POLICY & GOVERNMENT AFFAIRS

- Evaluate U.S. healthcare policy proposals and conduct thorough analyses to support the federal and state government affairs teams in formulating strategic policy positions across multiple therapeutic areas
- Support Bristol Myers Squibb engagement in pharmaceutical industry trade associations and other stakeholder initiatives related to critical public policy issues, with a focus on patient access to innovative medicines
- Develop a comprehensive understanding of how public policy issues impact the biopharmaceutical industry, patients, caregivers, providers, and the broader healthcare delivery system

GLOBAL PATIENT ADVOCACY

- Empower and embed patient experts and patient lived-experience throughout BMS's drug discovery, development, and delivery process primarily through strategic partnerships focused on disease and therapeutic awareness and increasing access and health equity around the world
- Support advocacy initiatives that educate patients and providers to better understand treatment options and novel therapies for patients with serious diseases
- Partner and engage with priority global patient advocacy organizations to increase awareness of emerging science and inform BMS strategy
- Ensure the patient voice is elevated and central in all BMS patient advocacy initiatives and resources, to best support access to care and overcome key barriers

PRECEPTORS:

- **Brian Lee, PharmD**
Senior Director, Immunology & Neuroscience Patient Advocacy
- **Aakash Patel, PharmD**
Director, Cardiovascular, Immunology Policy



BMS RESIDENCY

PHARMACEUTICAL INDUSTRY
RESIDENCY PROGRAM





Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency

The Bristol Myers Squibb Foundation's (BMSF) approach to addressing health inequities is to strengthen healthcare worker capacity, integrate medical care and community-based supportive services, and mobilize communities in the fight against serious illnesses. As Rutgers adjunct faculty through the Rutgers Institute for Pharmaceutical Industry Fellowship Program, there will be opportunities for the Resident to enhance their experience by collaborating with faculty through scholarship, publication, teaching and maintenance of clinical skills. During this 12-month residency, the PharmD Resident will spend approximately six months in southern Africa as part of the BMSF team with the Global Cancer Disparities-Africa program to help build capacity and provide training to partner organizations. Activities may include:

- Training of pharmacy and other health-care professionals in disease state management and pharmacotherapy
- Developing protocols and proposals incorporating the management of cancer from existing HIV/AIDS platforms
- Helping countries develop surveillance and registries to collect data and treatment recommendations especially as it relates to lung cancer
- Project implementation and management on field sites

The Resident will then complete the remainder of the program in Lawrence Township, New Jersey, working with the US-based teams on BMSF initiatives (including our US Health Disparities in Cardiovascular and Immunologic Diseases, Global Cancer Disparities - US/Brazil, and the Robert A Winn Diversity in Clinical Trials Award Program) that address health inequities in the United States. Activities may include:

- Researching issues for the development of grant program strategies
- Provide expert review and technical assistance for pharmacy related issues
- Connecting project goals with policy and advocacy advancement
- Reviewing grantee reports and learning responsibilities as a grant maker

APPLICATION REQUIREMENTS:

Applicants can pre-schedule an interview at the ASHP Midyear Clinical Meeting through PPS. Requirements include: PharmD from an ACPE-accredited institution, Completion of a PGY-1 residency or equivalent experience is strongly preferred, Curriculum vitae, Three letters of recommendation, Letter of intent addressing your interest in global/public health and long term plans, Candidates must be willing and able to relocate to southern Africa for 6 months

PRECEPTORS:

- **John Damonti**
Vice President, Corporate Philanthropy, Bristol Myers Squibb Foundation (US)
- **Christable Semondile**
Acting Director, Bristol Myers Squibb Foundation (South Africa)
- **Ornesha Watson, PharmD**
Senior Manager, Bristol Myers Squibb Foundation

Non-Recruiting Fellowships



WW HEOR - US MARKETS

**Tychell Branchcomb,
PharmD, MSc**

Second-Year Fellow
University of Florida College
of Pharmacy



WORLDWIDE COMMERCIAL

Christy Wong, PharmD

Second-Year Fellow
Keck Graduate Institute School
of Pharmacy and Health Sciences



GLOBAL MARKET ACCESS

William Ni, PharmD

Second-Year Fellow
University of Michigan College of
Pharmacy

Leadership Spotlight



Melissa Harris, PharmD

Executive Sponsor
Senior Vice President, Regional Clinical Operations
Fellowship Year 2001-2002

Bristol Myers Squibb is a great company for pharmacists who are wanting to enter the pharmaceutical industry. The company recognizes the value of the unique skill set, training, and experience that enables pharmacists to excel and rise to important management and leadership roles. The diversity and cohesiveness of our PharmD program, and our associated pharmacy community at Bristol Myers Squibb, provides an exceptional experience of seeing, doing, and teaching, which readily prepares our Fellows/Residents to become future leaders within both our Medical and Commercial organizations. As leaders at Bristol Myers Squibb, we appreciate the importance of attracting and retaining these talented individuals to fulfill the Bristol Myers Squibb Company mission of helping patients prevail over serious diseases. The Rutgers PharmD Fellowship Program is clearly an important part of our talent acquisition strategy and is key to building and cultivating an innovative and diverse workforce at Bristol Myers Squibb.



Priya Darouian, PharmD

Co-Steering Committee Lead
Director, Medical Innovation
Fellowship Year 2003-2004

The Bristol Myers Squibb fellowship program has provided me with a solid foundation that prepared me for a successful career in the pharmaceutical industry. As a Fellow, I was an integral part of my team and was provided with a breadth of experiences. My preceptors and mentors were truly invested in my career growth and development. The experiences and friendships I have gained throughout my fellowship and current role are invaluable and will last me a lifetime. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.



Thomas Lehman, PharmD

Co-Steering Committee Lead
Senior Director, WW Medical, Rheumatology
Fellowship Year 2012-2014

Selecting a fellowship at BMS was one of the best decisions I made to jump start my career during the fellowship interview and selection process. As a company with both a people and patient centric culture, a career at BMS for me has meant some of my proudest moments have had an impact for both patients and my career. Nearly a decade later, I look back on my time and think about the people both in the fellowship community and beyond who have helped me succeed and contributed to my professional development. I can recommend no better place to both start and grow your career.

Bristol Myers Squibb Fellowship Alumni

Medical

Adesumbo Odunlami Senior Manager, Global Health Equity Platform
Alex Brun Senior Director, US Medical Education
Alex Fletcher Senior Manager, US Medical, Cardiovascular
Anthony Salvatore Director, WW Medical, Oncology
Antonia Christodoulou Senior Manager, WW Medical, Rheumatology
Austin Bock Senior Manager, Medical Communications, Immunology
Boas Park Director, US Medical, Oncology
Brandon Elpers Director, WW Medical, Lung Fibrosis
Brielle Carramusa Clinical Scientist, Cardiovascular
Carmelo Alonso Associate Director, Medical Scientist, Oncology
Catherine Merrill Director, Medical Evidence Generation, Oncology
Divya Patel Senior Manager, US Medical, Oncology
Dorothy Zissler Associate Director, WW Scientific Publications, Immunoscience & Fibrosis
Franco Dickson Senior Manager, WW Scientific Publications, Melanoma
Ijeoma Oyetunde Director, WW Medical, Oncology
Irene Degutis Senior Director, US Medical Affairs, Hematology
Ivona Golczewska Director, Medical Communications, Oncology
Jaime Bunn Director, Scientific Communications & Engagement, Cardiovascular
Jagruhi Amin Associate Director, US Medical Promotional Review, Oncology
Jessie Ross Associate Director, Medical Scientist, Immunology
Joseph Kosto Associate Director, Franchise Medical Services
Josh Linton Associate Director, US Medical, Oncology
Jully Kim Senior Director, US Medical Promotional Review
Kaleen Barbary Director, Medical Communications, Lymphoma
Keith Wittstock Associate Director, US Medical Strategy, Immunology
Kiri Roland Associate Director, US Medical Promotional Review, Oncology
Lynn Anyaele Associate Director, Medical Education, Immunology
Marie Labib Senior Manager, WW Medical Affairs, Hematology
Max Prokopovich Associate Director, Medical Scientist, Oncology
Mina Awad Director, Medical Evidence Generation, Hematology
Nabomita Thomas Senior Director, US Medical, Oncology
Natanya Jennings Director, Global Health Equity Platform
Patrick Liu Associate Director, Franchise Medical Services, Hematology
Pavit Singh Director, US Medical Affairs, Hematology
Priya Darouian Director, Medical Innovation
Samantha Pomponi Associate Medical Director, Rheumatology
Sonie Lama Senior Director, Gastroenterology, US Medical
Sruthi Gaddam Director, WW Scientific Publications Team Lead, Oncology
Stella Han Senior Director, WW Medical, Cardiovascular
Swara Kasbekar Senior Manager, US Medical Promotional Review, Oncology
Thomas Lehman Senior Director, WW Medical, Rheumatology
Vincent Tran Associate Director, Medical Promotional Review, Hematology

Field Medical

Bryandt Douglas Senior Medical Science Liaison, Hematology
Bryce Adams Senior Medical Science Liaison, Oncology
Daniel Dilanji Senior Medical Science Liaison, Neurology
Gabriela Sikorska Medical Science Liaison, Dermatology
Jarred Rosenberg Medical Science Liaison, Cardiovascular
Johnathan Kloss Medical Science Liaison, Dermatology
Katherine Sprague Associate Director, US Field Medical Trainer, Cardiovascular
Khushbu S Shah Associate Director, US Field Medical Strategy, Hematology
Kim Tran Executive Director, US Field Medical, Hematology
Lauren Clouse Senior Medical Science Liaison, Dermatology
Raena Rhone Medical Science Liaison, Neurology
Teena John Medical Science Liaison, Neurology
Zack Inge Medical Science Liaison, Cardiovascular

BMS Foundation (Corporate Philanthropy)

Mason Chiang Senior Program Manager, BMS Foundation
Ornesha Watson Senior Program Manager, BMS Foundation

Commercial

Bernard Lee Director, US Commercial Analytics, Immunology
Chloe Thomas District Business Manager, Oncology
Christine Ghobrial Director, WW Commercial, Oncology
Dylan Atkinson Associate Director, US Marketing, Lung
Enoch Yue Associate Director, Worldwide Commercialization, Cardiovascular
Evelyn Abramson Senior Manager, US Marketing, Gastrointestinal
Frances Sousonis Senior Manager, US Marketing, Lung
Jade Hoang Director, US Eliquis Strategy, Operations and Commercial Model
Jake Kinley Senior Manager, US Marketing, Oncology
Justin Balint Executive Institutional Business Manager, Oncology
Karishma Patel Senior Manager, HCP Professional Education, Reblozyl Marketing
Kevin Kao Senior Product Manager, Channel Strategy & Marketing, Oncology
Lindsey McKeown Director, WW Commercial Strategy, Oncology
Matt Bunn Senior Director, Translational Medicine Transactions
Monica Anis Director, Global Alliances
Nina Johnson Senior Manager, US Marketing, Melanoma
Peter Fendt Associate Director, Customer & Market Insights, Hematology/CART
Spencer Heath Associate Director, Worldwide Commercial, Early Assets, BD and Strategy

Market Access & Pricing

Emily O'Neill Senior Manager, US Strategic Payer Marketing, Cardiovascular
Jennifer Liu Associate Director, US Access Marketing, Melanoma
Thushara Korattiyil Associate Director, WW Value and Segmentation

Regulatory Affairs

Alexander Cheung Senior Manager, US Commercial Regulatory Affairs
Amandeep Riar Associate Director, Global Regulatory Strategy, Hematology
Christine Alonso Director, US Commercial Regulatory Affairs, Oncology
Elsa Pan Senior Director, US Commercial Regulatory Affairs, Immunology/CV/Mature Brands
Robert Kalesnik-Orszulak Senior Director, Global Regulatory Strategy and Policy, Oncology
Sekayi Mushonga Vice President, Global Regulatory Strategy, Immunology & Neuroscience
Sohrab Sadeghi Senior Manager, Global Regulatory Strategy, Hematology
Trushna Shah Director, Regulatory Affairs, Immunology & Neuroscience
Yen Krystal Miao Associate Director, US Commercial Regulatory Affairs, Cardiovascular

Clinical

Amy Kim Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Andrew Mettias Clinical Scientist, Late Clinical Global Drug Development, Oncology
Brenda Yuan Clinical Scientist, Cell Therapy
Corey Rantz Clinical Scientist, Late Clinical Global Drug Development, Oncology
Corey Ritchings Clinical Development Lead, Oncology
Lana Mudarris Clinical Scientist, Cardiovascular
Maha Elgohail Senior Clinical Scientist, Cardiovascular
Melissa Harris Senior Vice President, Regional Clinical Operations
Nicholas Favatella Lead Clinical Scientist
Rebecca Fritz Clinical Scientist, Late Clinical Global Drug Development, Oncology
Sandhya Balachandar Senior Clinical Scientist, Oncology
Shannon Chandy Clinical Trial Lead, External Clinical Collaborations, Oncology
Trixia Camacho Executive Director, Clinical Development Team Leader, Oncology
Victoria Berger Senior Clinical Scientist, Immunology & Fibrosis
Will Jackson Senior Clinical Scientist, Late Clinical Global Drug Development

HEOR

Alex Sharer Associate Director, Field HEOR Scientist
Ashley Saunders Senior Manager, US HEOR, CART
Micah Anthony Senior Manager, WW HEOR Publications
Prianka Singh Director, WW HEOR, Oncology
Sumie Kakehi Senior Manager, US HEOR, Oncology

Policy & Advocacy

Aakash Patel Director, Cardiovascular & Immunology Policy
Shailee Gusani Senior Manager, Strategic Alliances & Issue Advocacy

ALUMNI

From Other Partner Companies

Medical

Amber Griffies (Roche) Director, Medical Communications, Hematology
Basirat Adeyemi (Merck) Senior Manager, Global Medical Affairs, Myeloid Leukemia
Christopher Russo (Pfizer) Associate Director, WW Medical, Cendakimab & Fibrosis
Irfan Tejani (Sanofi) Senior Director, WW Medical, Oncology
John Vaile (Bayer) Executive Director, Development Program Leader, Dermatology
Marta Molina (Bimark) Executive Director, Medical Communications, Immunology & Neuroscience
Omama Zubairi (Daiichi Sankyo) Associate Director, Medical Scientist, Oncology
Ralu Vlad (Roche) Vice President, Medical Evidence Generation
Sapna Patel (Novo Nordisk) Associate Director, WW Scientific Publications, Oncology
Shalon Jones (Dr. Reddy's Laboratories) Director, Global Medical Affairs, Myeloid

Field Medical

Hiba Malik (J&J) Specialist, Field Medical Communications, Hematology
Joseph Fulginiti (Acorda) Senior Medical Science Liaison, Neurology
Samantha Kaufman (J&J) Medical Science Liaison, Oncology
Sheiva Ghazanfari Khavari (Roche) Executive Medical Science Liaison, Dermatology
Thomson Korattiyil (Pfizer) Medical Science Liaison, Oncology

Commercial

Akash Lall (Nevakar), Senior Manager, Customer & Market Insights, Immunology
Alberta Drake (Daiichi Sankyo) Senior Manager, Customer & Market Insights, Hematology
Amanda Bright (Novartis) Associate Director, Acute Myeloid Leukemia Marketing, Hematology
Brittney Rule (Bayer) Associate Director, Worldwide Marketing, Immunology
Bryan Campbell (Novartis) Vice President, Cell Therapy Brand & Franchise Strategy
Christina Yuan (Bayer) Associate Director, US Multiple Myeloma Marketing, Hematology
Jessica Cairns (Roche) Vice President, WW Hematology Commercial, Strategy, Business Development and Early Assets
Kevin Crona (Bayer) Associate Director, Business Development Analytics
Kirolous Makarios (Merck) Associate Director, Competitive Intelligence, Oncology
Norhaan Khalil (J&J) Senior Manager, US Oncology GU Marketing
Peter Chan (Bayer) Associate Director, US Product Marketing, Hematology
Tiffany Chow (J&J) Associate Director, Competitive Intelligence, Oncology

Market Access & Pricing

Joseph Lee (TJU/J&J) Director, WW Market Access Strategy Lead, Cardiovascular
Karen Shieh (Novo Nordisk) Associate Director, WW Value and Segmentation, Oncology
Lucy Eichenblatt (J&J) Director, WW Pricing Strategy, Oncology
Parth Vashi (Bayer) Director, WW Market Access Strategy Lead, Neurology & Gastroenterology
Samaneh Kalirai (Eli Lilly) Director, Healthcare Strategy & Pricing Analytics

Regulatory Affairs

Andro Shenouda (Merck) Director, Global Regulatory Strategy Lead, Oncology
Angela Tang (Roche) Associate Director, Global Scientific and Regulatory Documentation
Charles Frost (Roche) Senior Director, Global Scientific & Regulatory Documentation
David Nguyen (J&J) Director, Global Regulatory and Safety Sciences Lead, Oncology
Jateh Major (Merck) Associate Director, Regulatory Affairs, Oncology
Jennifer Dudinak (Roche) Senior Vice President, Global Regulatory Sciences
Kenneth Hu (Sanofi) Senior Manager, Global Regulatory Strategy & Policy, Oncology
Mark Hanna (Merck) Associate Director, Intercontinental Regulatory Strategy Lead, Oncology
Matthew Wong (Daiichi-Sankyo) Senior Director, Global Regulatory Strategy, Hematology
Nitin Kumar (Regeneron) Associate Director, Global Regulatory Strategy & Policy, Immunology
Omar Khalid (Allergan) Senior Director, Global Regulatory Strategy Team Leader, Oncology
Parth Patel (J&J) Associate Director, Global Regulatory Lead, Oncology
Shih-Yi Kim (J&J) Executive Director, Global Regulatory Affairs, Immunology
Vrunda Patel (Bayer) Director, Global Regulatory Strategy and Policy, Immunology & Neuroscience

Commercial Regulatory Affairs

Akshay Patel (Novartis) Associate Director, US Commercial Regulatory Affairs, Cardiovascular
Cole Cecchini (Novartis) Senior Manager, Commercial Regulatory Affairs, Advertising and Promotion
Jeff Sniggs (Acorda) Associate Director, Commercial Regulatory Affairs
Nicole Coccia (Novartis) Senior Manager, Commercial Regulatory Affairs, Advertising and Promotion

Corporate Affairs

Kate Bender (Novartis) Director, Investor Relations

Clinical

Gabrielle Guancione (Merck) Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Geetha Pudusery (Novartis) Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Jennifer Han (Novartis) Clinical Scientist, Early Clinical Development
Jennifer Poon (Merck) Director, Clinical Capabilities Lead, Clinical Center of Excellence
Jenny Wong (Roche) Senior Director, Global Feasibility Solid Tumor
Jesse Siegel (Merck) Senior Clinical Scientist, Late Global Drug Development
Joseph Fiore (Merck) Executive Director, Global Program Lead, Oncology
Julia Spiridigliozzi (Merck) Senior Clinical Scientist, Oncology
Leena Shah (TKL Research) Executive Director, Global Program Lead, Immunology
Mackenzie Minogue (J&J) Clinical Scientist, Early Clinical Development
Margee Kyada (Genentech) Clinical Scientist
Matthew Lamb (UNC) Vice President, Development Head, Immunology & Fibrosis
Michelle Hudson (Novartis) Vice President, Global Drug Development Strategic Operations & Clinical Center of Excellence
Naomey Sarkis (Novartis) Senior Clinical Scientist, Early Clinical Development
Ronak Patel (Pfizer) Director, Early Development Project Manager
Samer Karam (Merck) Senior Clinical Scientist, Late Clinical Global Drug Development
Sanjukta Basu (Bayer) Senior Manager, Global Feasibility, Immunology
Sapna Chhagan (Novartis) Senior Director, Clinical Scientist, Cell Therapy Therapeutic Area Lead, Early Clinical Development, Oncology/Hematology/Cell Therapy
Vani Vegesna (Pfizer) Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Whitney Handy (Merck) Clinical Scientist, Early Clinical Development

HEOR

Karishma Shelley (TJU/Novartis) Associate Director, US HEOR, Oncology
KayOnda Bayo (Eli Lilly) Associate Director, US HEOR, Field
Laetitia N'Dri (TJU/Novartis) Senior Manager, US HEOR, Immunology
Miraj Patel (Sanofi) Director WW HEOR, Oncology
Uchekukwu Mordi (Eli Lilly) Associate Director, US HEOR, Field

Policy & Advocacy

Brian Lee (Sanofi) Senior Director, Patient Advocacy, Immunology & Neuroscience
Jonathan Naylor (Sanofi) Associate Director, Patient Advocacy, Oncology

*Not an Exhaustive List

**Last Updated – July 2023

Bristol Myers Squibb Component

The Fellows will become an integral part of their respective teams and will be trained to manage a broad range of responsibilities, similar to those managed by current team members. This fellowship program will necessitate interaction and teamwork with departments in all aspects of the corporation, such as Global Pharmacovigilance and Labeling, Sales, Medical Affairs, Marketing, Regulatory Services, Legal, Clinical Trials, Post-Marketing Clinical Research, and Health Care Channel Management. While at Bristol Myers Squibb, the Fellows will participate in various teambuilding activities and attend leadership development lectures with senior management. Key fellowship activities within Bristol Myers Squibb include:

MENTORSHIP PROGRAM

Participate in a mentorship program with senior management and fellowship alumni to discuss career development, networking, organization structure, market/industry knowledge, etc.

LUNCH AND LEARN SERIES

Attend lunch and learn series with executive sponsors and senior management to have interactive discussions.

BRISTOL MYERS SQUIBB FELLOWSHIP COMMITTEES

Lead and take part in the various fellowship committees such as: Co-Chief Fellows, Recruitment, Community Development, Professional Development, Alumni, and Scholarship committee.





Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey



Joseph A. Barone,
Pharm.D., F.C.C.P.

Dean and Professor II
Ernest Mario School of
Pharmacy
Rutgers University



Carolyn Seyss,
Pharm.D., RUCIF

Fellowship Director
Institute for Pharmaceutical
Industry Fellowships
Ernest Mario School of Pharmacy



Michael Toscani,
Pharm.D.

Research Professor, Fellowship
Director Emeritus
Institute for Pharmaceutical
Industry Fellowships

Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the [Institute for Pharmaceutical Industry Fellowships](#) to enhance and promote the role of pharmacists in industry through the RPIF Program.

The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**. Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.



Connect with us on social
media: @RutgersFellow



Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTERs** the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

**F
O
S
T
E
R**

Family of Leading Companies – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.

Outstanding Alumni Track Record – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.

Strong Network — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.

Trusted and Proven Since 1984 — the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.

Enhanced Career Development – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.

Rigorous Academic Component – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The [Ernest Mario School of Pharmacy \(EMSOP\)](#) is part of Rutgers Biomedical and Health Sciences (RBHS), the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry



Connect with us on social
media: @RutgersFellow



Application Process and Eligibility Requirements:

Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

How to Apply:

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **October 6, 2023** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

Your Letter of Intent & Letters of Recommendation should be addressed to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Required Items	Submit By
Application with short-answer questions	October 13th
Letter of Intent (LOI)	October 13th
Curriculum Vitae (CV)	October 13 th
Letters of Recommendation (LORs)	December 1 st



Alliance of Industry Fellowship Associates Fellowship Offers

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, AIFA exists to promote a common aspect of each of our program's cultures by supporting a consensus first offer date of December 13, 2023 for all fellowship candidates.

We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.



Connect with us on social media: @RutgersFellow